investor_presentation
Axel Springer
Loading viewer...
investor_presentation
Format: PDF investor_presentation
1 40thAnnual JP Morgan Healthcare Conference –Jan 10, 2022 Breakthroughs that change patients’ livesAdvancing Our mRNA Strategic Development 40thAnnual JP Morgan HealthCare Conference Albert Bourla, DVM, PhD CEO & Chairman January 10, 2022
1 40thAnnual JP Morgan Healthcare Conference –Jan 10, 2022 Breakthroughs that change patients’ livesAdvancing Our mRNA
Strategic Development
40thAnnual JP Morgan HealthCare
Albert Bourla, DVM, PhD
January 10, 2022 2 40thAnnual JP Morgan Healthcare Conference –Jan 10, 2022 Breakthroughs that change patients’ livesForward -Looking Statements and Other Notices
This presentation includes forward- looking statements about, among other topics, Pfizer's mRNA strategy and pipeline portfolio; Pfizer’s collaboration agreement with
BioNTech to co- develop a shingles mRNA vaccine; Pfizer’s collaboration with Beam Therapeutics for base editing for certain rare diseases; Pfizer’s option agreement with
Acuitas to non- exclusively license LNP technology; Pfizer’s research collaboration with Codex DNA for its synthetic DNA technology ; our efforts torespond toCOVID -
19,including Comirnaty ; our anticipated future operating andfinancial performance ,business plans andprospects ;ourability tosuccessfully capitalize ongrowth
opportunities andprospects ;andother statements about ourbusiness ,operations andfinancial results thatareeach subject tosubstantial risks and uncertainties
thatcould cause actual results todiffer materially from those expressed orimplied by such statements .Among other things ,statements regarding revenue and earnings
pershare growth ;thedevelopment orcommercial potential ofourproduct pipeline ,in-line products, product candidates andadditional indications, including expected
clinical trialprotocols ,thetiming oftheinitiation andprogress ofclinical trials anddata read- outs from trials ;thetiming forthe submission of applications for and
receipt ofregulatory approvals ;expected breakthrough, best orfirst-in-class orblockbuster status ofourmedicines or vaccines; andthe anticipated benefits of our
lightspeed approach to research and development of certain areas ofourproduct pipeline ,are forward looking and are estimates that are subject to change and
clinical trialandregulatory success. These statements are subject to risks, uncertainties and other factors that may cause actual results to differ materially f rompast
results, future plans and projected future results.
Additional information regarding these and other factors can be found in Pfizer’s Annual Report on Form 10- K for the fiscal year ended December 31, 2020 and in our
subsequent reports on Form 10- Q, including in the sections thereof captioned “Risk Factors” and “Forward- Looking Information and Factors That May Affect Future
Results”, as well as in our subsequent reports on Form 8- K, all of which are filed with the U.S. Securities and Exchange Commis sion and available at www.sec.gov and
Potential risks and uncertainties also include the impact of COVID -19 on our sales and operations, including impacts on employees, manufacturing, supply chain, research
Preview truncated — download the full document for the complete content.
investor_presentation
129 Pages
investor_presentation
25 Pages
VIA optronics
investor_presentation
Axel Springer